Katy Beckermann, Medical Director of GU Clinical Research at Tennessee Oncology shared on X:
”TAMs get blamed for immune evasion in kidney cancer.
Here, more of them trended with a better response to first-line nivolumab.
- HCRN GU16-260, tested first-line nivolumab monotherapy with salvage ipi in metastatic ccRCC n=72 ccRCC:
- CD163+ TAM density, OR 2.21, PFS HR 0.77
- Nonexhausted CD8+ TILs: OR 1.54, PFS HR 0.79. TLS density moved the same way, PFS HR 0.92
- PD-1+ Tregs ran opposite: high fraction, PFS 3.4 vs 10.9 months
Combined, they split outcomes better than alone. Hypothesis-generating, not a validated assay continues to argue for multi-marker panels in future trials.
Emphasis on amazing team work and learning from every patient about biology on every trial.”
Title: Dissecting the Tumor Microenvironment to Identify Biomarkers of Outcome to Anti–PD-1 Therapy in Clear-Cell Renal Cell Carcinoma: Analyses of the HCRN GU16-260 Trial
Authors: Nourhan El Ahmar, Morgan A. Paul, Berkay Simsek, Sayed Matar, Opeyemi A. Jegede, Yasmin Nabil Laimon, Varunika Savla, Razan Mohanna, Gabriel Roberti de Oliveira, Aseman Bagheri Sheshdeh, Thomas Denize, Destiny J. West, Maxwell D. Seager, Maxine Sun, Toni K. Choueiri, Wanling Xie, Gordon J. Freeman, Arlene H. Sharpe, David A. Braun, Naomi B. Haas, Hans Hammers, Mehmet A. Bilen, Mark Stein, Jeffrey A. Sosman, Catherine J. Wu, David F. McDermott, Michael B. Atkins, Sabina Signoretti
Other articles featuring Katy Beckermann on OncoDaily.